A flexible strategy for testing subgroups and overall population

被引:53
作者
Alosh, Mohamed [1 ]
Huque, Mohammad F. [2 ,3 ]
机构
[1] FDA, CDER, OTS, Off Biostat,Div Biometr 3, Silver Spring, MD 20993 USA
[2] FDA, CDER, OTS,OB, Div Biometr 4, Silver Spring, MD 20993 USA
[3] Georgia So Univ, Adjunct Fac, Jiann Ping Hsu Coll Publ Hlth, Statesboro, GA 30460 USA
关键词
subgroup analysis; study power; dependence; significance levels for the subgroup analysis; PIOGLITAZONE CLINICAL-TRIAL; MULTIPLE END-POINTS; MACROVASCULAR EVENTS; ADJUSTMENT;
D O I
10.1002/sim.3461
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Subgroup analyses in addition to the total study population analysis are common in clinical trials. However, it is well recognized that findings from subgroup analyses do not provide confirmatory evidence for subgroup treatment effects without placing a priori criteria for ensuring that their findings are scientifically we address some of the common pitfalls of subgroup analyses. Subgroups analyses sound. In this paper inherently have low power for detecting treatment effects. We investigate the power interplay for a Subgroup analysis and that for the total study population and list factors that impact the power of a subgroup analysis. Then we introduce a flexible statistical strategy for testing a pre-specified sequence of hypotheses for both the overall and a subgroup. The proposed method strongly controls the familywise Type I error rate and enjoys higher power than other traditional methods. This testing strategy allows testing for a subgroup once a pre-specified degree of consistency in the efficacy findings between the subgroup and the overall study population is met. In addition, it accounts for the dependency between test statistics for the subgroup and the overall study population. We discuss the power performance of this new method and provide significance levels for Subgroup analysis. Finally, we illustrate its application through retrospective analysis of data from three published clinical trials. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:3 / 23
页数:21
相关论文
共 22 条
  • [1] [Anonymous], 2003, MULTIPLE ANAL CLIN T
  • [2] Biesheuvel Egbert H E, 2003, J Biopharm Stat, V13, P663, DOI 10.1081/BIP-120024201
  • [3] *CPMP, 2002, CPMPEWP90899 EMEA
  • [4] DEGRAMONT A, 2005, AM SOC CLIN ONC ASCO
  • [5] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
    Dormandy, JA
    Charbonnel, B
    Eckland, DJA
    Erdmann, E
    Massi-Benedetti, M
    Kmoules, IK
    Skene, AM
    Tan, MH
    Lefébvre, PJ
    Murray, GD
    Standl, E
    Wilcox, RG
    Wlhelmsen, L
    Betteridge, J
    Birkeland, K
    Golay, A
    Heine, RJ
    Korányi, L
    Laakso, M
    Mokán, M
    Norkus, A
    Pirags, V
    Podar, T
    Scheen, A
    Scherbaum, W
    Schernthaner, G
    Schmitz, O
    Skrha, J
    Smith, U
    Taton, J
    [J]. LANCET, 2005, 366 (9493) : 1279 - 1289
  • [6] Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
    Gordon, AN
    Tonda, M
    Sun, S
    Rackoff, W
    [J]. GYNECOLOGIC ONCOLOGY, 2004, 95 (01) : 1 - 8
  • [7] Subgroup analyses in randomized clinical trials: Statistical and regulatory issues
    Grouin, JM
    Coste, M
    Lewis, J
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2005, 15 (05) : 869 - 882
  • [8] A flexible fixed-sequence testing method for hierarchically ordered correlated multiple endpoints in clinical trials
    Huque, Mohammad F.
    Alosh, Mohamed
    [J]. JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2008, 138 (02) : 321 - 335
  • [9] Koch G.G., 1997, J BIOPHARM STAT, V7, P323, DOI 10.1080/10543409708835190
  • [10] Moyé LA, 2000, STAT MED, V19, P767, DOI 10.1002/(SICI)1097-0258(20000330)19:6<767::AID-SIM518>3.0.CO